Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?

Indian Journal of Medical Microbiology

Volumn 30, Issue 4, 2012, Pages 448-452

  Simsek F ^a   Gedik, H ^a   Yildirmak, M T ^a   Iris, N E ^a   Turkmen A ^a   Ersoy, A ^a   Ersoz M ^a   Gucuyener A ^a  

^a OKMEYDANI TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acinetobacter baumannii; Colistin; Mortality; Response; Treatment

Indexed keywords

ANTIBIOTIC AGENT; COLISTIMETHATE; COLISTIN; NEOMYCIN; RIFAMPICIN;

ACINETOBACTER INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84871284355     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.103767     Document Type: Article

References (20)

1. Playford EG, Craig JC, Iredell Jr. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and consequences. J Hosp Infect 2007;65: 204-11.
2. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94: 281-8.
3. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infectious due to multidrug resistant gram negative bacteria in patients without cyctic fibrosis. Antimicrob Agents Chemother 2005;49: 3136-46.
4. Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old an recent studies. Crit Care 2006;10: R27.
5. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrugresistant Acinetobacter baumannii isolated from ventilatorassociated pneumonia. Int J Antimicrob Agents 2008;32: 29-32.
6. Clinical Laboratory Standards Institute performance standards for antimicrobial susceptibility testing: Seventh informational supplement M100-S17. Wayne, Pennsylvania, USA: Clinical Laboratory Standards Institute; 2007.
7. Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old an recent studies. Crit Care 2006;10: R27.
8. Gaynes RP, Horan TC. Surveillance of nosocomial infections. Appendix A: CDC definitions of nosocomial infections. In: Mayhall CG, editor. Hospital epidemiology and infection control. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 1296-7.
9. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61: 417-20.
10. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35: 194-9.
11. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study. Crit Care Med 2010;38: 1651-64.
12. David MD, Gill MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother 2008;61: 962-4.
13. Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009;65: 188-91.
14. Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. Clinical Outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai 2011;94: 863-9.
15. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: Experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010;43: 323-31.
16. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: A matched case-control study. Clin Infect Dis 2010;51: 1238-44.
17. Katsaragakis S, Markogiannakis H, Samara E, Pachylaki N, Theodoraki EM, Xanthaki A, et al. Predictors of mortality of Acinetobacter baumannii infections: A 2-year prospective study in a Greek surgical intensive care unit. Am J Infect Control 2010;38: 631-5.
18. Lim SK, Lee SO, Choi SH, Choi JP, Kim SH, Jeong JY, et al. The outcomes of using colistin for treating multidrug resistant acinetobacter species bloodstream infections. J Korean Med Sci 2011;26: 325-31.
19. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13: 818-29.
20. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1: 14-20.